Anaplastic Astrocytoma Market Report 2026

The anaplastic astrocytoma market size has grown strongly in recent years. It will grow from $0.46 billion in 2025 to $0.49 billion in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to improvements in brain tumor diagnostics, availability of neurosurgical treatment options, expansion of oncology treatment centers, growing clinical trial participation, increased use of radiotherapy.

The anaplastic astrocytoma market size is expected to see strong growth in the next few years. It will grow to $0.64 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to increasing investments in neuro-oncology research, rising adoption of precision medicine approaches, expansion of targeted and adjunct therapies, growing focus on early detection strategies, increasing collaboration between research institutions. Major trends in the forecast period include increasing adoption of multimodal treatment approaches, rising use of advanced neuroimaging tools, growing focus on personalized oncology therapies, expansion of clinical research activities, enhanced integration of surgical and radiotherapy protocols.

The increasing incidence of primary malignant and non-malignant brain tumors is expected to drive the growth of the anaplastic astrocytoma market in the coming years. Brain tumors are abnormal growths in the brain that can be classified as either cancerous (malignant) and invasive or non-cancerous (benign) and non-invasive, with varying levels of aggressiveness and potential to spread. Treatment of anaplastic astrocytoma involves removing the tumor along with surrounding affected tissue while preserving brain function. For example, in March 2023, the American Society of Clinical Oncology (ASCO), a US-based non-profit organization, reported that approximately 24,810 adults in the United States were expected to be diagnosed with primary cancerous tumors originating in the brain and spinal cord, including 14,280 cases in men and 10,530 in women. Consequently, the rising incidence of primary malignant and non-malignant brain tumors is expected to support the growth of the anaplastic astrocytoma market.

Key companies in the anaplastic astrocytoma market are focusing on developing advanced combination therapies to improve overall survival and progression-free survival in patients with recurrent disease. Combination therapy involves using two or more drugs to target cancer pathways simultaneously, enhancing treatment effectiveness and slowing tumor progression. For instance, in November 2024, Orbus Therapeutics, a US-based biopharmaceutical company, launched a combination of eflornithine and lomustine in its Phase 3 STELLAR study. This therapy showed clinically meaningful improvements in overall survival and progression-free survival for patients with grade 3 IDH mutant astrocytoma, achieving a median overall survival of 34.9 months compared to 23.5 months with lomustine alone, and a median progression-free survival of 15.8 months versus 7.2 months. The treatment leverages eflornithine’s ability to irreversibly inhibit ornithine decarboxylase, a key enzyme in polyamine biosynthesis, enhancing its cytostatic effect. The study included over 343 patients across North America and Europe and demonstrated significant clinical benefit in a challenging patient population, offering a promising new option for recurrent anaplastic astrocytoma.

In July 2025, NeOnc Technologies Holdings, Inc., a US-based clinical-stage biotechnology company developing treatments for anaplastic (Grade III) astrocytoma, partnered with Quazar Investment to accelerate CNS therapy development and regional commercialization in the MENA region. The partnership aims to expand NeOnc’s CNS-focused clinical and commercial presence across the UAE and MENA, advancing its NEO100 and NEO212 programs with regional funding and support for infrastructure and clinical trials. Quazar Investment is a UAE-based investment firm that supports high-growth life sciences initiatives.

Major companies operating in the anaplastic astrocytoma market are Pfizer Inc., Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol Myers Squibb, AstraZeneca, Eli Lilly and Company, Johnson & Johnson, Eisai Co. Ltd, AbbVie Inc., Bayer AG, Amgen Inc., Ipsen SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Ltd., Dr Reddy’s Laboratories Ltd., Novocure Ltd., Celldex Therapeutics Inc.

North America was the largest region in the anaplastic astrocytoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anaplastic astrocytoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anaplastic astrocytoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the anaplastic astrocytoma market by increasing costs of imported diagnostic imaging equipment, radiotherapy systems, surgical tools, and oncology pharmaceuticals. Hospitals and cancer treatment centers in North America and Europe are most affected due to reliance on imported high-value medical technologies. These tariffs are raising treatment costs and capital expenditure requirements. However, they are also encouraging domestic production of medical equipment, regional oncology drug manufacturing, and increased investment in localized neuro-oncology treatment infrastructure.

The anaplastic astrocytoma market research report is one of a series of new reports that provides anaplastic astrocytoma market statistics, including anaplastic astrocytoma industry global market size, regional shares, competitors with a anaplastic astrocytoma market share, detailed anaplastic astrocytoma market segments, market trends and opportunities, and any further data you may need to thrive in the anaplastic astrocytoma industry. This anaplastic astrocytoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anaplastic astrocytoma is a rare, malignant brain tumor that develops from astrocytes, the supportive cells of the nervous system. It can lead to neurological symptoms such as headaches, seizures, behavioral changes, and motor deficits, which are typically managed through a combination of surgery, radiation therapy, and chemotherapy.

The main classifications of anaplastic astrocytoma are Grade I, Grade II, Grade III, and Grade IV. Grade I tumors are the least aggressive, generally considered benign, and are typically treated through surgical excision along with routine monitoring and follow-up. Treatment options for anaplastic astrocytoma also include surgery, chemotherapy, and radiation, with therapies categorized into pre-registration and clinical trial phases for use in hospitals, clinics, retail pharmacies, and online pharmacies.

The anaplastic astrocytoma market consists of revenues earned by entities by providing targeted therapies, genetic testing and biomarker analysis, clinical trials and healthcare services. The market value includes the value of related goods sold by the service provider or included within the service offering. The anaplastic astrocytoma market also includes sales of surgical equipment, imaging devices and radiation therapy equipment that are used in providing anaplastic astrocytoma treatment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.